Iqvia Stock Price, News & Analysis (NYSE:IQV)

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) issued its quarterly earnings data on Wednesday, July, 24th. The medical research company reported $1.39 EPS for the quarter, topping the Zacks' consensus estimate of $1.38 by $0.01. The medical research company had revenue of $2.74 billion for the quarter, compared to analysts' expectations of $2.70 billion. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. The firm's quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.29 earnings per share. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Monday, October 28th 2019. View Earnings Estimates for Iqvia.

Iqvia issued an update on its FY19 earnings guidance on Wednesday, July, 24th. The company provided earnings per share (EPS) guidance of $6.25-6.45 for the period, compared to the Thomson Reuters consensus estimate of $6.33. The company issued revenue guidance of $11.00-1.15 billion, compared to the consensus revenue estimate of $11.02 billion.

18 analysts have issued 1 year price objectives for Iqvia's stock. Their predictions range from $136.38 to $180.00. On average, they anticipate Iqvia's stock price to reach $164.49 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price. View Analyst Price Targets for Iqvia.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Press coverage about IQV stock has been trending neutral this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Iqvia earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Iqvia.

Iqvia saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,630,000 shares, an increase of 42.9% from the August 30th total of 3,240,000 shares. Based on an average daily volume of 1,240,000 shares, the short-interest ratio is currently 3.7 days. Approximately 2.6% of the shares of the stock are sold short. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE) and Eloxx Pharmaceuticals (ELOX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), Micron Technology (MU), Workday (WDAY), NIC (EGOV) and Zoetis (ZTS).

Iqvia's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Artemis Investment Management LLP (0.14%), DNB Asset Management AS (0.06%), State of Alaska Department of Revenue (0.04%), Three Peaks Capital Management LLC (0.02%), Assenagon Asset Management S.A. (0.01%) and Sumitomo Mitsui DS Asset Management Company Ltd (0.01%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Artemis Investment Management LLP, Gateway Investment Advisers LLC, Three Peaks Capital Management LLC, Lucia Wealth Services LLC, Financial Gravity Wealth Inc., Bremer Bank National Association and Winslow Evans & Crocker Inc.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Pacer Advisors Inc., Sumitomo Mitsui DS Asset Management Company Ltd, First Hawaiian Bank, Foundations Investment Advisors LLC, Campbell & CO Investment Adviser LLC, DNB Asset Management AS and Crossmark Global Holdings Inc.. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $145.02.

Iqvia has a market capitalization of $28.41 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]